For patients

Information for patients

The GA-VAX project, funded by the European Commission, is dedicated to developing a vaccine for genetic C9orf72 ALS and FTD. Led by DZNE and Intravacc, our team is building on promising preclinical results and actively working on the scientific, manufacturing, and regulatory steps needed to bring this therapy to human trials in the coming years.

While progress is encouraging, it is important to note that we are still in the early stages of development. Several critical steps remain before the vaccine can be tested in patients, and new challenges may arise along the way. Our the team is highly optimistic that we can reach the goal of delivering a vaccine that is ready for human studies and deeply appreciates the support from the European Commission. We hope this project will eventually lead to a new treatment for C9orf72 ALS and FTD. However, even if successful, it will take several years before the vaccine is available to the public.

Due to data protection regulations, we cannot maintain a list of patients interested in participating in future trials. For updates, please visit www.ga-vax.eu periodically. In the meantime, you may want to consider participating in the DZNE clinical registry study (https://www.dzne.de/en/research/studies/clinical-studies/describe/).

General information about ALS and FTD is available on the DZNE website:

For medical inquiries, diagnosis, or treatment, please consult your neurologist or visit our affiliated ALS clinics.

We are also grateful for donations to the ALS foundation at DZNE – “Karin Christiane Conradi Stiftungsfonds für ALS-Forschung”. Your contribution can help drive groundbreaking research forward: https://www.dzne-stiftung.de/spendenprojekte/#c174

Thank you for your interest in and support of the GA-VAX project!